Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00506415 · ClinicalTrials.gov registry record · Phase 3

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

A Phase 3 study of Alzheimer Disease, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
1,584
Enrollment target
20
Study locations

NCT00506415 is a Phase 3 study of Alzheimer Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,584 participants, below the 2,746-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00506415, a Phase 3 study of Alzheimer Disease, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
1,584 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Rivastigmine 5 cm^2
  • DRUG Rivastigmine 10 cm^2
  • DRUG Rivastigmine 15 cm^2
  • DRUG Placebo to 15 cm^2 patch
  • DRUG Placebo to 10 cm^2 patch

Study Locations (20)

California

  • Novartis investigative site - Anaheim
  • Novartis investigative site - Carson
  • Novartis investigative site - Costa Mesa
  • Novartis investigative site - Fullerton
  • Novartis investigative site - La Habra
  • Novartis investigative site - La Jolla
  • Novartis investigative site - National City
  • Novartis investigative site - Redlands
  • Novartis investigative site - San Francisco

Florida

  • Novartis investigative site - Boca Raton
  • Novartis investigative site - Bradenton
  • Novartis investigative site - Deerfield Beach
  • Novartis investigative site - Delray Beach
  • Novartis investigative site - Fort Lauderdale

Arizona

  • Novartis investigative site - Gilbert
  • Novartis investigative site - Phoenix
  • Novartis investigative site - Sun City

Colorado

  • Novartis investigative site - Fort Collins
  • Novartis investigative site - Longmont

Alabama

  • Novartis investigative site - Birmingham

Trial Details

FieldValue
Enrollment Target 1,584 participants
Start Date 2007-06
Est. Completion 2011-05
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00506415

The ClinicalTrials.gov registry entry for NCT00506415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,584 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,746-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (42% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Rivastigmine 5 cm^2 is the first listed.

NCT00506415 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00506415 about?

NCT00506415 is a clinical study titled "Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline". The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.

What is the current status of trial NCT00506415?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,584 participants. The study started on 2007-06. Estimated completion is 2011-05.

What conditions does trial NCT00506415 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT00506415?

The interventions under investigation include: Rivastigmine 5 cm^2 (DRUG), Rivastigmine 10 cm^2 (DRUG), Rivastigmine 15 cm^2 (DRUG), Placebo to 15 cm^2 patch (DRUG), Placebo to 10 cm^2 patch (DRUG).

Who is sponsoring clinical trial NCT00506415?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00506415 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.